TL;DR: The American Brachytherapy Society (ABS) as mentioned in this paper provided updated guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachyther therapy (PPB).

TL;DR: The American Brachytherapy Society (ABS) as discussed by the authors provided updated recommendations for locally advanced (Federation of Gynecology and Obstetrics Stages IB2-IVA) cervical cancer based on literature review and clinical experience.

TL;DR: The clinical outcomes for HDR are excellent, with high rates of biochemical control, even for high-risk disease, with low morbidity.

TL;DR: Recommendations are made for interstitial brachytherapy for vaginal cancer and recurrent disease in the vagina and practitioners and cooperative groups are encouraged to use these recommendations to formulate treatment and dose-reporting policies.

TL;DR: In this study of patients with low and intermediate risk of prostate cancer, comparable outcomes at 5 years were noted between modalities with increased costs associated with IMRT.

TL;DR: The American Brachytherapy Society (ABS) as discussed by the authors developed a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose rate (PDR) brachythermapy for locally advanced cervical cancer.

TL;DR: Increased VR(100), presence of acute rectal toxicity, and learning curve were associated with higher rate of late RTOG ≥2 toxicity, which was rare after prostate brachytherapy.

TL;DR: In the subset of patients treated with (125)I monotherapy, D(90) higher than 140Gy was associated with improved biochemical tumor control compared with lower doses, and a nomogram predicting PSA-RFS was developed based on these predictors.

TL;DR: Initial results of 3D HDRB using the authors' fractionation schedule in the treatment of vaginal cancers showed good local response with acceptable morbidities.

TL;DR: This survey does suggest an evolution in the practice of LDR brachytherapy since 1998 and aids in identifying aspects that require further progress or investigation.

TL;DR: There is a solid scientific rationale for the application of available strategies to the radiation patient for erectile function preservation after treatment with RT, and basic science and clinical studies support the concept of a structured program of erectile tissue preservation.

TL;DR: HDR-ISBT may achieve good LC in gynecologic cancer unsuitable for ICB, especially in primary malignancies with a 2-year LC rate higher than 85%.

TL;DR: US is comparable to MR for preimplant prostate delineation, with no significant difference in volume and dimensions.

TL;DR: The results suggest that HDRBT and PDRBT constitute a safe alternative in the palliative treatment of patients with locally or regionally recurrent head and neck cancers with a relapse in a previously irradiated area, which were not qualified or rejected surgery.

TL;DR: Treatment of early-stage breast cancer patients with breast-conserving therapy using a 2-day radiation dose schedule resulted in acceptable chronic toxicity and similar clinical outcomes as standard 5-day fractionation.

TL;DR: The approach of a single implantation procedure followed by five fractions of HDRBT was well tolerated with early results demonstrating a moderate response and local control rate with acceptable toxicities.

TL;DR: The ability to achieve in-field local control in this poor prognostic cohort was associated with improved survival outcomes, and IORT dose >15Gy should be used to increase the likelihood of disease control.

TL;DR: Three-dimensional CT-based planning for high-dose rate vaginal cuff brachytherapy helps to decrease dose to critical organs without compromising coverage of CTV by customizing the dosimetry according to individual patient anatomy.

TL;DR: Heterogeneity corrections on high-dose rate plans were found to have only a small dosimetric impact over TG-43-based dose calculations for both conventional Point-A and volume-optimized plans.

TL;DR: Combined treatment of choroidal melanoma with ruthenium BT and simultaneous TTT seems to provide higher local control, eye-globe preservation, and recurrence-free survival rates than treatment with BT alone and results in similar rates of metastases and overall survival.

TL;DR: There were no differences in acute or long-term genitourinary or gastrointestinal toxicity between (125)I and (103)Pd in combined modality therapy for prostate cancer and additional followup of these patients is needed.

TL;DR: A urethral sparing-focused planning solution using IPSA reduces mean urethra dose by 34%, as compared with IPSA-generated plans based on the RTOG 0321 protocol, while maintaining prostate coverage and critical structure dose.

TL;DR: Permanent interstitial brachytherapy usually with supplemental EBRT and androgen deprivation therapy results in excellent biochemical control and cause-specific survival in the most unfavorable subset of high-risk prostate cancer patients.

TL;DR: This retrospective series suggests that interstitial perineal HDRB is a safe and effective treatment option for primary or locally recurrent gynecological malignancies and a valuable option in patients who have received previous EBRT to the pelvis, achieving good local control with acceptable late treatment-related side effects.

TL;DR: With one of the largest patient populations to date comparing WBI and APBI, no difference in RR or OS was noted between WBI or APBI treatment and these data support the continued use of APBI on protocol and off protocol in appropriately selected patients.

TL;DR: The multilumen device led to improvements in target coverage and normal structure doses compared with traditionally accepted guidelines and similar toxicities were seen compared with single-lumen devices, even in patients with skin and rib spacing <7mm.

TL;DR: A technique that modifies the geometry by noninvasive direct intervention of native-type hyaluronate to create and maintain a distance between the prostate and the rectum and decrease rectal size during treatment is developed.

TL;DR: IGABT is increasingly becoming the standard of care for the treatment of locally advanced cervical cancer gradually replacing prescription to Point A, and has higher rates of local tumor control in advanced stage disease also with extensive parametrial boost.

TL;DR: Interestingly, at 4-Gy radiation, NCI-H446 cells were more sensitive to LDR 125I irradiation than HDR irradiation, and this sensitivity could be further enhanced by WM treatment.